277 related articles for article (PubMed ID: 17347513)
1. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
2. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
[TBL] [Abstract][Full Text] [Related]
3. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
5. The role of protein tyrosine phosphatase 1B in Ras signaling.
Dubé N; Cheng A; Tremblay ML
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1834-9. PubMed ID: 14766979
[TBL] [Abstract][Full Text] [Related]
6. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Dubé N; Bourdeau A; Heinonen KM; Cheng A; Loy AL; Tremblay ML
Cancer Res; 2005 Nov; 65(21):10088-95. PubMed ID: 16267035
[TBL] [Abstract][Full Text] [Related]
7. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
8. A role for the scaffolding adapter GAB2 in breast cancer.
Bentires-Alj M; Gil SG; Chan R; Wang ZC; Wang Y; Imanaka N; Harris LN; Richardson A; Neel BG; Gu H
Nat Med; 2006 Jan; 12(1):114-21. PubMed ID: 16369543
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
[TBL] [Abstract][Full Text] [Related]
10. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice.
Jacquemart IC; Springs AE; Chen WY
Int J Oncol; 2009 Feb; 34(2):517-28. PubMed ID: 19148488
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
[TBL] [Abstract][Full Text] [Related]
12. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance.
Balavenkatraman KK; Aceto N; Britschgi A; Mueller U; Bence KK; Neel BG; Bentires-Alj M
Mol Cancer Res; 2011 Oct; 9(10):1377-84. PubMed ID: 21849469
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.
Meyer DS; Aceto N; Sausgruber N; Brinkhaus H; Müller U; Pallen CJ; Bentires-Alj M
Oncogene; 2014 Jan; 33(3):398-402. PubMed ID: 23318421
[TBL] [Abstract][Full Text] [Related]
14. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
Nørgaard P; Law B; Joseph H; Page DL; Shyr Y; Mays D; Pietenpol JA; Kohl NE; Oliff A; Coffey RJ; Poulsen HS; Moses HL
Clin Cancer Res; 1999 Jan; 5(1):35-42. PubMed ID: 9918200
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
16. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.
Wong AW; Dunlap SM; Holcomb VB; Nunez NP
Alcohol Clin Exp Res; 2012 Apr; 36(4):577-87. PubMed ID: 21981381
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression.
Hardy S; Wong NN; Muller WJ; Park M; Tremblay ML
Cancer Res; 2010 Nov; 70(21):8959-67. PubMed ID: 20841483
[TBL] [Abstract][Full Text] [Related]
18. Neu-mediated phosphorylation of protein tyrosine phosphatase epsilon is critical for activation of Src in mammary tumor cells.
Berman-Golan D; Elson A
Oncogene; 2007 Oct; 26(49):7028-37. PubMed ID: 17486066
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E.
Bowe DB; Kenney NJ; Adereth Y; Maroulakou IG
Oncogene; 2002 Jan; 21(2):291-8. PubMed ID: 11803472
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice.
Elson A
Oncogene; 1999 Dec; 18(52):7535-42. PubMed ID: 10602512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
